TrialPanorama/TrialPanorama-database huggingface dataset:
Study: NCT02847910

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: the disposable tissue suction set
Description: Induced abortion is a main backstop for terminating unwanted pregnancies, however, traditional hard metal instruments has lots of insufficiencies such as easily tissue damage, and repeatedly sterilization increases the incidence of cross infection in the hospital what leads to more complications of pelvic inflammation, infertility and so on. Therefore disposable non-metallic instruments are desperately needed as a way to decrease the complications and provide better medical services to patients. So, the investigators want to explore the clinical effect of disposable tissue suction tube set and make comparison with traditional metal instruments.

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: traditional metal instruments of abortion
Description: Induced abortion is a main backstop for terminating unwanted pregnancies. In Chinese hospital, traditional metal instruments are always used during the surgery. So the investigators want to explore the clinical effect of disposable tissue suction tube set and make comparison with traditional metal instruments.
Study: NCT02927353

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: DMB-3113
Description: subcutaneously injected in a single dose of 40 mg.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Adalimumab
Description: subcutaneously injected in a single dose of 40 mg.
Study: NCT04442152

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: MenCare+/Bandebereho fathers'/couples' group education
Description: MenCare+/Bandebereho is a 3 year project to engage men in maternal, newborn and child health (MNCH) and in sexual and reproductive health in Rwanda. A core component of the project is fathers'/couples' group education. The target participants were first-time parents or parents of young children living in 16 rural and semi-urban sectors selected by the implementing partner in collaboration with local authorities. The MenCare+/Bandebereho fathers'/couples' group education engages men in 15 weekly sessions of group discussion, critical reflection and interactive activities led by a trained facilitator using a curriculum developed by RWAMREC and Promundo and approved by the Rwandan Ministry of Health, adapted from the Program P Manual. Men's partners participate in 6-8 sessions. The sessions focus on men's role in MNCH, family planning, sharing household responsibilities, intimate partner violence, conflict resolution, family budgeting, and gender equality.
Study: NCT00877539

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: PF-03526299
Description: Inhaled, two doses 4 hours apart

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Inhaled, two doses 4 hours apart

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Fluticasone propionate
Description: Inhaled
Study: NCT00657657

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Engerix™-B
Description: A challenge dose of hepatitis B vaccine will be administered to all subjects as a deep intramuscular injection in the deltoid region of the non-dominant arm.

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Engerix™-B
Description: A challenge dose of hepatitis B vaccine will be administered to all subjects as a deep intramuscular injection in the deltoid region of the non-dominant arm.

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Engerix™-B
Description: A challenge dose of hepatitis B vaccine will be administered to all subjects as a deep intramuscular injection in the deltoid region of the non-dominant arm.

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Engerix™-B
Description: A challenge dose of hepatitis B vaccine will be administered to all subjects as a deep intramuscular injection in the deltoid region of the non-dominant arm.
Study: NCT02211664

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Passeo-18 balloon

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Passeo-18 Lux drug releasing balloon

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Pulsar-18 stent
Study: NCT02548663

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Sport therapy
Description: Frequency: 60 min three times/week~1. 20 min: aerobic training on bicycle ergometer.~2. 20 min: strength training at 60% of maximal load.~3. 20 min: proprioception and stretching exercises.

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Osteopathic treatment
Description: Frequency: 60 min weekly
Study: NCT02080364

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Azeliragon
Description: Azeliragon 5mg administered orally, once daily for 18 months

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Placebo administered orally, once daily for 18 months
Study: NCT02787681

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: NEMO Gauge
Description: Measurement and adjustment of endotracheal tube position by stylet.
Study: NCT02058589

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Herpes Zoster vaccine GSK1437173A
Description: 2 doses administered intramuscularly (IM) in the deltoid region of the non-dominant arm.

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: 2 doses administered intramuscularly (IM) in the deltoid region of the non-dominant arm.
Study: NCT01613144

Intervention type: DEVICE
Intervention: OsseoScrew Spinal Fixation System
Description: Surgical intervention
Study: NCT00770744

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Zicronapine
Description: 5-7mg/day; orally, encapsulated tablets, once daily
Study: NCT03585972

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Frailty Prevention Program
Description: 4 face-to-face sessions, with a occupational therapist over 4 months to address function, safety, social participation, diet, exercise, sleep, and medication management. Sessions are expected to last between 60-120 minutes. The first session is a comprehensive occupational therapy evaluation and treatment plan. Sessions 2 and 3 involved physical activity and dietary education, counseling and goal setting. Session 4 involves reviewing program progress, and setting maintenance goals.
Study: NCT05754671

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: perceptual assessment of the recorded voice sample
Description: perceptual assessment of the recorded voice samples

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: voice recording
Description: voice recording
Study: NCT00939588

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Aliskiren/ Valsartan

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Telmisartan/ Ramipril
Study: NCT00770744

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Olanzapine
Description: 10-15mg/day; orally, encapsulated tablets, once daily
Study: NCT02690116

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Qigong/Tai Chi Easy
Description: Classes will be at two different times of day (to accommodate working and non-working participants). Participants will attend one 60 minute class per week for the 8 weeks, with a recommended home practice time of 2 1/2 hours each week.

Intervention type: OTHER
Group type: SHAM_COMPARATOR
Intervention: Sham Qigong
Description: Classes will be at two different times of day (to accommodate working and non-working participants). Participants will attend one 60 minute class per week for the 8 weeks, with a recommended home practice time of 2 1/2 hours each week.

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Educational Support
Description: Class times and at-home readings correspond to dose set for the QG/TCE and SQG class times and home practice. Participants will attend one 60-minute class per week for the 8 weeks, with a recommended home practice time (reading, workbook completion) of 2 1/2 hours each week.
Study: NCT03615053

Intervention type: OTHER
Group type: OTHER
Intervention: Implementation of WAPPS-Hemo personalized dosing regimen
Description: Twelve months after enrollment in the study, WAPPS-Hemo will be used to calculate each patients individual pharmacokinetic estimate. Once completed, the WAPPS-Hemo clinical calculator will be used to calculate the optimal regimen based on individual needs.
Study: NCT01133080

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Minocycline
Description: minocycline 200 mg/day orally in two divided doses for the second week. From weeks 3 to weeks 5, minocycline 400 mg/day orally in two divided doses.

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: placebo
Description: placebo 200 mg/day orally in two divided doses for the first week. placebo 200 mg/day orally in two divided doses for the second week.~From weeks 3 to weeks 5, placebo 400 mg/day orally in two divided doses.
Study: NCT05840068

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: MetFORMIN 500 Mg Oral Tablet
Description: MetFORMIN 500 Mg Oral Tablet

Intervention type: DRUG
Group type: OTHER
Intervention: Chemotherapy
Description: The standard chemotherapy protocol developed by the South Egypt Cancer Institute (SECI).

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Chemotherapy
Description: The standard chemotherapy protocol developed by the South Egypt Cancer Institute (SECI).
Study: NCT00171912

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: imatinib mesylate
Study: NCT01451502

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Umbilical Cord Blood (UCB)
Description: Infusion of Minimally Manipulated UCB Units - the UCB unit will be infused through a central line according to institutional guidelines.
Study: NCT04848818

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Distal radial metaphyseal fracture fixation with percutaneous K-wires
Description: Pediatric distal metaphyseal fractures which are severly displaced will be operated with percutaneous K-wires..

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Distal radial and/or ulnar metaphyseal fracture fixation with bidegradable PLGA-based (Activa Im-Nail) implants
Description: Pediatric distal metaphyseal radial and /or ulnar fractures which are severly displaced will be operated with percutaneous bidegradable PLGA-based (Activa Im-Nail) implants.
Study: NCT01016847

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Montelukast
Description: 10 mg Q day

Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Sugar pill
Description: Sugar pill that looks like Montelukast that will be given Q day
Study: NCT04351308

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: MAPI chemotherapy
Description: AP = Doxorubicin (Adriamycin) 37.5 mg/m2/day \* 2day (total/cycle 75 mg/m²)~+ Cisplatin 120 mg/m2/course (total/cycle 120 mg/m²) ; M = Methotrexate 12000 mg/m2 (total/cycle 12000 mg/m²) with leucovorin rescue; I = Ifosfamide 2400 mg/m2/day \*5day (total/cycle 12000 mg/m²)

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: MAPI chemotherapy
Description: AP = Doxorubicin (Adriamycin) 37.5 mg/m2/day \* 2day (total/cycle 75 mg/m²)~+ Cisplatin 120 mg/m2/course (total/cycle 120 mg/m²) ; M = Methotrexate 12000 mg/m2 (total/cycle 12000 mg/m²) with leucovorin rescue; I = Ifosfamide 2400 mg/m2/day \*5day (total/cycle 12000 mg/m²)

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: MAPI chemotherapy
Description: AP = Doxorubicin (Adriamycin) 37.5 mg/m2/day \* 2day (total/cycle 75 mg/m²)~+ Cisplatin 120 mg/m2/course (total/cycle 120 mg/m²) ; M = Methotrexate 12000 mg/m2 (total/cycle 12000 mg/m²) with leucovorin rescue; I = Ifosfamide 2400 mg/m2/day \*5day (total/cycle 12000 mg/m²)

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Apatinib Mesylate
Description: anti-angiogenesis tyrosine kinase inhibitors 500 mg orally daily

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Camrelizumab
Description: anti-PD-1 antibody 200mg ivgtt. Q2W
Study: NCT02079025

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: High-resolution ultrasound guided prostate biopsy
Description: Ultrasound guided prostate biopsy using ultra-high resolution ultrasound system

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Standard ultrasound guided prostate biopsy
Description: Ultrasound guided prostate biopsy using standard of care ultrasound system
Study: NCT03566745

Intervention type: DIAGNOSTIC_TEST
Intervention: Blood for protein activity
Description: Blood for protein activity

Intervention type: DIAGNOSTIC_TEST
Intervention: Blood for protein activity
Description: Blood for protein activity
Study: NCT03265353

Intervention type: OTHER
Group type: OTHER
Intervention: Moderate Potassium/Low Sodium Diet
Description: 7 days of the prescribed diet

Intervention type: OTHER
Group type: OTHER
Intervention: Moderate Potassium/High Sodium Diet
Description: 7 days of the prescribed diet

Intervention type: OTHER
Group type: OTHER
Intervention: High Potassium/High Sodium Diet
Description: 7 days of the prescribed diet
Study: NCT04196634

Intervention type: OTHER
Intervention: Risk assessment
Description: People on sick leave due to musculoskeletal conditions will be screened for potential risk factors for prolonged sickness absence. No intervention will be given.
Study: NCT04276051

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Cryoablation of the Vagus Nerve
Description: The Visual ICE Cryoablation System is a mobile console system intended for cryoablative tissue destruction using a minimally invasive procedure. The Visual-ICE System uses high-pressure argon gas that circulates through closed-tip cryoablation needles to induce tissue freezing. Active tissue thawing is achieved by circulating helium gas through the needles or, alternatively, by the use of Galil Medical i-Thaw technology. The procedure will be done under CT guidance and involves a 4-5 mm scalpel incision followed by percutaneous probe placement about the posterior gastroesophageal junction (the location of the posterior vagal trunk). The probe will create a zone of decreased temperature (-20 to -40 degrees Celsius) involving the posterior vagal nerve fibers/plexus. The cryoablation process will include a 3-minute freeze, followed by a 1-minute thaw, and a second 3-minute freeze and 1 minute thaw.

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Lifestyle Intervention
Description: The lifestyle intervention structure will include three face-to-face counseling sessions at baseline, 3 and 6 months. Dietary counseling to follow a low carbohydrate diet will be provided by a registered dietitian. Focus will be on increasing fruits and vegetables and decreasing refined sugars and processed foods. It will also include motivational interviewing, goal setting and nutrition education. In addition, subjects will be encouraged by exercise physiologist to slowly increase physical activity to at least 150 minutes weekly. There will be weekly phone calls or texts (participants' choice) providing a total of 26 points of contact recommended by the United States Preventive Services Task Force.

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Lifestyle Intervention
Description: The lifestyle intervention structure will include three face-to-face counseling sessions at baseline, 3 and 6 months. Dietary counseling to follow a low carbohydrate diet will be provided by a registered dietitian. Focus will be on increasing fruits and vegetables and decreasing refined sugars and processed foods. It will also include motivational interviewing, goal setting and nutrition education. In addition, subjects will be encouraged by exercise physiologist to slowly increase physical activity to at least 150 minutes weekly. There will be weekly phone calls or texts (participants' choice) providing a total of 26 points of contact recommended by the United States Preventive Services Task Force.
Study: NCT05661318

Intervention type: OTHER
Intervention: Risk assessment
Description: Collect clinical, laboratoary and genetics data from the participants after informed consent
Study: NCT03462862

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: PEEK
Description: PEEK has been successfully used over the last years in the medical ﬁeld, and orthopedics, speciﬁcally. which presents high bio compatibility, good mechanical properties, high temperature resistance, and chemical stability due to a 4 GPa modulus of elasticity, it is as elastic as bone and can reduce stresses transferred to the abutment teeth.Additional advantages of this polymer material are elimination of allergic reactions and metallic taste, high polishing qualities, low plaque afﬁnity, and good wear resistance, it has only recently been used in dentistry.

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Bre-Flex
Description: In the recent time thermoplastic materials become quite popular in clinical practice such as nylon and acetal resins. since the 1950, poly-amide resin (nylons) provide improved esthetics and reduction of rotational forces on the abutment teeth due to their low elastic modulus(3).~The major disadvantage of a nylon removable denture is the inability for a reline procedure and the lack of occlusal rests as well as rigid frameworks, that could lead to occlusal instability and sinking, especially in Kennedy class I and II cases. On the other hand, acetal resins present adequate mechanical strength to form a frame-work more rigid than nylon with retentive clasps, connectors, and supportive elements; however, the acetal resin material lacks natural translucency and vitality.
Study: NCT00566891

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: tirofiban
Description: tirofiban high dose bolus 25µ/Kg

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Clopidogrel
Study: NCT04081064

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: 10-week exercise programme based on aerobic interval and resistance training
Description: The intervention will take place over 10 weeks. Participants will complete three sessions per week; each sessions will be scheduled at least 24 hours apart. Two sessions per week will consist of aerobic interval exercise and resistance training, and one session per week will consist of aerobic interval exercise only.

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: 10-week exercise programme based on aerobic interval and resistance training
Description: The intervention will take place over 10 weeks. Participants will complete three sessions per week; each sessions will be scheduled at least 24 hours apart. Two sessions per week will consist of aerobic interval exercise and resistance training, and one session per week will consist of aerobic interval exercise only.
Study: NCT03647761

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Tetra-grip
Description: Tetra-grip is a tubular elastic bandage that provides both compression and support
Study: NCT00763490

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Full intensity, double umbilical cord, stem cell transplant
Description: stem cell transplant using two umbilical cord blood units, combined with a Flu/Bu4 conditioning regimen prior to transplantation

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Flu/Bu4 conditioning regimen
Description: Fludarabine: 40 mg/m² daily on days -5, -4, -3, -2~Busulfan: 3.2 mg/kg IV daily on days -5, -4, -3, -2

Intervention type: RADIATION
Group type: EXPERIMENTAL
Intervention: Total Lymphoid Irradiation (TLI)
Description: one dose, 400 cGy,on day -1 or day 0, prior to cord blood infusion

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Graft versus Host Disease prevention (GVHD prophylaxis)
Description: Tacrolimus for GVHD (Graft Versus Host Disease Prevention) Tacrolimus - will begin on day -3 (IV or oral) for at least 180 days. Target trough level for tacrolimus is 8-12 ng/ml. In the absence of GVHD, tacrolimus tapering will begin on day +56 post transplant.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Mycophenolate Mofetil
Description: Mycophenolate Mofetil (MMF) for GVHD prophylaxis. MMF - will be given at a dose of 10mg/kg IV q 8 hours if the patient weight is more than 50 kg, or 15 mg/kg IV q 8 hours if less than 50 kg, beginning the morning of day -3. (If renal failure and Glomerular Filtration Rate (GFR) \< 25 mL/min, the dose should not exceed 1 gm every 8 hours. (No dose adjustment for liver disease is required.) MMF should be given via IV until oral medications are tolerated.~MMF will be stopped at Day +28 if no acute GVHD is seen by that time. If there is not any donor cell engraftment, MMF will be continued as directed by the attending physician. If the patient has active acute GVHD requiring systemic therapy, MMF may be continued.